Drug Trial Radar · NCT07037901
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
405
Planned (sponsor's estimate)
Start
Jun 17, 2025
Primary completion
Dec 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- Inmagene LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
Conditions
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
Interventions
IMG-007Drug
Participants will receive IMG-007 subcutaneously.
PlaceboDrug
Participants will receive a placebo subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change from baseline in EASI at Week 24Time frame: Baseline, Week 24
Locations
33 sites in 4 countries. Site status is shown where the registry gives one.
Inmagene Site 1
Lancaster, California · Recruiting
Inmagene Site 23
Los Angeles, California · Recruiting
Inmagene Site 19
Ocala, Florida · Recruiting
Inmagene Site 4
Tampa, Florida · Recruiting
Inmagene Site 2
Rolling Meadows, Illinois · Recruiting
Inmagene Site 6
Kew Gardens, New York · Recruiting
Inmagene Site 21
New York, New York · Recruiting
Inmagene Site 11
Woodbury, New York · Recruiting
Inmagene Site 20
Charlotte, North Carolina · Recruiting
Inmagene Site 10
Fargo, North Dakota · Recruiting
Inmagene Site 9
Columbus, Ohio · Recruiting
Inmagene Site 5
Mayfield Heights, Ohio · Recruiting
Inmagene Site 3
Portland, Oregon · Recruiting
Inmagene Site 12
Anderson, South Carolina · Recruiting
Inmagene Site 8
Southlake, Texas · Recruiting
Inmagene Site 7
Burien, Washington · Recruiting
Inmagene Site 31
Coorparoo, Australia · Not yet recruiting
Inmagene Site 33
Fremantle, Australia · Not yet recruiting
Inmagene Site 32
Westmead, Australia · Not yet recruiting
Inmagene Site 25
Woden, Australian Capital Territory, Australia · Not yet recruiting
Inmagene Site 28
Liverpool, New South Wales, Australia · Not yet recruiting
Inmagene Site 26
Benowa, Queensland, Australia · Not yet recruiting
Inmagene Site 27
Carlton, Victoria, Australia · Not yet recruiting
Inmagene Site 24
Mitcham, Victoria, Australia · Not yet recruiting
Inmagene Site 15
Surrey, British Columbia, Canada · Recruiting
Inmagene Site 22
Vancouver, British Columbia, Canada · Recruiting
Inmagene Site 17
Greater Sudbury, Ontario, Canada · Recruiting
Inmagene Site 13
Mississauga, Ontario, Canada · Recruiting
Inmagene Site 18
North Bay, Ontario, Canada · Recruiting
Inmagene Site 14
Montreal, Quebec, Canada · Recruiting
Inmagene Site 16
Saskatoon, Saskatchewan, Canada · Recruiting
Inmagene Site 30
Auckland, New Zealand · Not yet recruiting
Inmagene Site 29
Hamilton, Waikato Region, New Zealand · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.